We are live on ! Find out more
KCM

Knoll Capital Management Portfolio holdings

AUM $180M
1-Year Est. Return 66.11%
This Fund
S&P 500
This Quarter Est. Return
+17.85%
1 Year Est. Return
+66.11%
3 Year Est. Return
+268.55%
5 Year Est. Return
+741%
10 Year Est. Return
+10,877.35%
AUM
$224M
AUM Growth
+$31.2M
Cap. Flow
-$858K
Cap. Flow %
-0.38%
Top 10 Hldgs %
99.68%
Holding
17
New
1
Increased
–
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
PVCT
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
+$240K

Top Sells

Rank Stock Value
1
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$809K
2
PRKR
Parkervision Inc
PRKR
+$240K
3
AKTX
Akari Therapeutics
AKTX
+$45.8K
4
ECTE
ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE)
ECTE
+$2.98K

Sector Composition

Rank Sector Weight
1 Healthcare 21.41%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MDVN
1
DELISTED
MEDIVATION, INC.
MDVN
$176M 78.3%
4,559,038
– –
AMPE
2
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
$24.8M 11.03%
9,881
– –
ARCT icon
3
Arcturus Therapeutics
ARCT
$157M
$11.9M 5.3%
98,143
– –
KERX
4
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$3.08M 1.37%
200,000
– –
TOVX icon
5
Theriva Biologics
TOVX
$10.2M
$2.39M 1.07%
155
– –
LUMO
6
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$2.06M 0.92%
8,604
– –
NWBO
7
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
$1.34M 0.6%
200,300
– –
INO icon
8
Inovio Pharmaceuticals
INO
$79.8M
$1.11M 0.49%
8,507
– –
ADXS
9
DELISTED
Advaxis Inc
ADXS
$709K 0.32%
15,000
– –
GLMD icon
10
Galmed Pharmaceuticals
GLMD
$3.94M
$633K 0.28%
361
– –
NRX
11
DELISTED
NEPHROGENEX INC COM
NRX
$301K 0.13%
50,000
– –
PVCT
12
DELISTED
PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT
$172K 0.08%
+200,000
New +$240K
ADXSW
13
DELISTED
Advaxis Inc Warrants
ADXSW
$115K 0.05%
112,500
– –
AKTX
14
Akari Therapeutics
AKTX
$15.2M
$78K 0.03%
2
-1
-33% -$45.8K
ECTE
15
DELISTED
ECHO THERAPEUTICS, INC. NEW COMMON STOCK (DE)
ECTE
$62K 0.03%
27,430
-1,200
-4% -$2.98K
PRKR
16
DELISTED
Parkervision Inc
PRKR
– –
-5,000
Closed -$240K
MACK
17
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
– –
-20,410
Closed -$809K

Similar funds

MGWA
Monument Group Wealth Advisors Concord, Massachusetts $180M AUM 19.81% 1-Year Est. Return
AW
Alchemi Wealth Essex, Connecticut $180M AUM
FBC
Fairfield, Bush & Co Darien, Connecticut $180M AUM 39.51% 1-Year Est. Return
AIC
Aurora Investment Counsel Atlanta, Georgia $180M AUM 0.3% 1-Year Est. Return
AG
Amiral Gestion Paris, France $180M AUM 9.43% 1-Year Est. Return
PCA
Prospect Capital Advisors Sausalito, California $180M AUM 60.99% 1-Year Est. Return
HIC
Hamrick Investment Counsel Seattle, Washington $180M AUM
FFA
Frazier Financial Advisors Columbus, Ohio $181M AUM 11.16% 1-Year Est. Return

Knoll Capital Management's Q2 2014 Portfolio in Review

As of Q2 2014, Knoll Capital Management held 17 positions worth $224M, up 16% from $193M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Knoll Capital Management's Q2 2014 filing shows 1 new, 2 reduced and 2 closed positions. Its largest new stake was PROVECTUS BIOPHARMACEUTICALS, INC. (DE): 200,000 shares worth $172K. The largest sale was Merrimack Pharmaceuticals, Inc., an estimated $809K.

By sector, the portfolio is most concentrated in Healthcare at 21% of assets, down from 24% a quarter earlier, followed by Technology.

  • Knoll Capital Management's largest Q2 2014 buy was PROVECTUS BIOPHARMACEUTICALS, INC. (DE): 200,000 shares worth $172K.
  • Knoll Capital Management's biggest Q2 2014 reduction was Akari Therapeutics, cutting an estimated $45.8K.
  • Knoll Capital Management fully exited Merrimack Pharmaceuticals, Inc. in Q2 2014, selling an estimated $809K.
  • Knoll Capital Management's ten largest holdings make up 100% of its $224M portfolio in Q2 2014.
  • Knoll Capital Management opened 1 new position and closed 2 in Q2 2014.
  • Knoll Capital Management's portfolio value rose 16% quarter-over-quarter to $224M.

Based on Knoll Capital Management's 13F filing for Q2 2014, filed 14 Aug 2014.